The cyclophosphamide treatment of glomerulonephritis patients
Dorets'kyĭ, V.V.
Vrachebnoe Delo 2: 51-53
1991
ISSN/ISBN: 0049-6804 PMID: 2058123 Document Number: 374080
An analysis is presented of direct results of monotherapy with cyclophosphamide of 70 patients suffering of acute and chronic glomerulonephritis. The treatment proved effective in 10% of patients. It was established that the initially reduced levels of immunoglobulins G and A in the blood serum of patients with glomerulonephritis are a prognosis-positive factor for the use of cyclophosphamide.
Document emailed within 1 workday
Related Documents
Wańkowicz, Z.; Tymowicz, J.; Korsak, J. 1998: Therapeutic plasma exchanges with cyclophosphamide in the treatment of rapidly progressing glomerulonephritis Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 5(29): 304-306Duman, V.L. 2002: Therapeutic effect of cyclophosphamide in patients with chronic glomerulonephritis with nephrotic syndrome Terapevticheskii Arkhiv 74(6): 39-41
Tang, Z.; Zhou, H.; Yao, X.; Hu, W.; Leishi, L. 1997: Effects of methylprednisolone and cyclophosphamide pulse therapy on renal infiltrating cells in patients with crescentic glomerulonephritis Chinese Medical Journal 110(3): 206-209
Jungers, P.; Dougados, M.; Tron, F.; Leibowitch, J.; Lesavre, P.; Droz, D.; Bach, J.F. 1979: Long-term course of 32 cases of diffuse proliferative lupus glomerulonephritis, treated with corticoids alone or combined with cyclophosphamide Journal d'Urologie et de Nephrologie 85(12): 855-858
Adam, Z.; Szturz, P.; Křen, L.; Krejčí, M.; Pour, L.; Svoboda, T.; Hanke, I.; Penka, I.; Koukalová, R.; Rehák, Z.; Cervinková, I.; Storková, T.; Král, Z.; Mayer, J. 2013: PET-CT documented fast onset of treatment response to cyclophosphamide, thalidomide and dexamethasone in patients with multicentric Castlemans disease. Case description and treatment information overview Vnitrni Lekarstvi 59(4): 301-312
Jardine, I.; Fenselau, C.; Appler, M.; Kan, M.N.; Brundrett, R.B.; Colvin, M. 1978: Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy Cancer Research 38(2): 408-415
Wetzels, J.F.M. 2004: Cyclophosphamide-induced gonadal toxicity: a treatment dilemma in patients with lupus nephritis? Netherlands Journal of Medicine 62(10): 347-352
Chu, S.J.; Chang, D.M.; Kuo, S.Y.; Hsu, C.M.; Chen, C.M.; Chang, M.L. 1994: Intermittent intravenous treatment of lupus nephritis with cyclophosphamide: a four-year experience with twenty-four patients Zhonghua Yi Xue Za Zhi 53(6): 325-330
Hainsworth, J.D.; Wolff, S.N.; Stein, R.S.; Greer, J.P.; Cousar, J.B.; Greco, F.A. 1986: Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis Cancer Treatment Reports 70(8): 953-958
Bezwoda, W.R.; Rastogi, R.B. 1994: A randomized comparative study of cyclophosphamide, vincristine, doxorubicin, and prednisolone and cyclophosphamide, vincristine, mitoxantrone, and prednisolone regimens in the treatment of intermediate- and high-grade lymphoma with 8 years' follow-up Seminars in Hematology 31(2 Suppl 3: 3
Trifard, F.; Chrétien, Y.; Vallantin, X.; Collet, C.; Lachand, A.T.; Dufour, B. 1988: [Neoadjuvant chemotherapy (cisplatin, doxorubicin, cyclophosphamide) in the treatment of invasive urothelial tumors of the bladder. Preliminary results of a prospective study concerning 22 patients Annales d'Urologie 22(3): 216-219
Angrilli, F.; Pennese, E.; Di Marzio, A.; Liberatore, E.; Di Lorenzo, R.; Fioritoni, G. 2002: A dexamethasone, vinblastine, cyclophosphamide, etoposide, methotrexate and bleomycin (D-VICEMB) protocol as first-line treatment of patients aged 70 years or older affected by intermediate/high grade non-Hodgkin's lymphoma Haematologica 87(11): 1227-1229
Jovanović, D.; Marić, M.; Pantović, R. 1992: Early treatment of acute nephrotic syndrome in patients with acute post-streptococcal glomerulonephritis Vojnosanitetski Pregled 49(4): 335-338
Trouillas, P.; Neuschwander, P.; Nighoghossian, N.; Adeleine, P.; Tremisi, P. 1989: Intensive immunosuppression in progressive multiple sclerosis. An open study comparing 3 groups: cyclophosphamide, cyclophosphamide-plasmapheresis and control subjects. Results after 3 years Revue Neurologique (Paris) 145(5): 369-377
West, R.J.; Zweig, S.F. 1997: Meta-analysis of chemotherapy regimens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide European Journal of Gynaecological Oncology 18(5): 343-348
Larbre, F. 1970: Attempt to determine the role of glomerulonephritis in the etiology of prolonged glomerulonephritis in children Pediatrie 25(6): 693-695
Ganguly, N.K.; Singhal, P.C.; Tewari, S.C.; Nath, I.V.; Sharma, S.; Mahajan, R.C.; Palit, S.K.; Chugh, K.S. 1979: Serum immunoglobulin in glomerulonephritis with a special reference to minimal lesion glomerulonephritis Journal of the Association of Physicians of India 27(11): 1003-1008
Sakalová, A.; Hrubisko, M. 1975: Cyclophosphamide in the treatment of immune hemocytopenias Folia Haematologica 102(5): 559-564
Scetbon, V. 1973: Incoercible hematuria due to prolonged treatment with cyclophosphamide Journal d'Urologie et de Nephrologie 79(12 Part 2): 472-476
Zephir, H.; De-Seze, J.; Senechal, O.; Stojkovic, T.; Ferriby, D.; Delisse, B.; Dubus, B.; Verier, A.; Hautecoeur, P.; Vermersch, P. 2002: Treatment of progressive multiple sclerosis with cyclophosphamide Revue Neurologique (Paris) 158(1): 65-69